F2G Biotech
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, F2G Biotech sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
F2G Biotech: 4 sponsored US clinical trials, none currently recruiting.
F2G Biotech sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Invasive Aspergillosis, with 1 trials.
Upper-quartile sponsor footprint
F2G Biotech sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Olorofim Aspergillus Infection Study
NCT05101187
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
NCT05200286
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
NCT04752540
Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
NCT03583164
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
How the F2G Biotech early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).
Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Invasive Aspergillosis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
F2G Biotech: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
F2G Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this F2G Biotech page
4 registered trials is a research-attention snapshot, not an endorsement of F2G Biotech or any single study.
- None of F2G Biotech's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Invasive Aspergillosis is the condition F2G Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Invasive Aspergillosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. F2G Biotech pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.